BioGend (6733) conducting an initial public offering of stock on April 3,2019
BioGend (6733) applied for the first public offering of shares to the Taipei Exchange, which took effect on April 3, 2019 and the amount of shares is NT$820,000...
Issuance of common stock is NT$428,679,000, the total paid-up capital is NT$700,000,000
Biphasic Cartilage Repair Implant (RevoCart) Clinical Trial Has Successfully Completed Patient Enrollment
Exactech Taiwan is merged into BioGend
BioGend is recognized as a Biotech and New Pharmaceutical Company by Industrial Development Bureau (IDB)
BioGend Therapeutics signed the Australia and New Zealand exclusively distribution and co-development agreement
Osteo-inductive-factor (OIF)/TCP in rabbit ulnar defect model - CT
Biphasic Cartilage Repair Implant (RevoCart)
The Biphasic Cartilage Repair Implant (RevoCart) is a type of articular cartilage regeneration and repair technique with autograft cartilage tissue.
At BioGend, we see opportunities that others have yet to identify — and we have the vision and determination to explore new frontiers, transforming ideas previously considered impossible into reality. We care patients with neglected needs and that’s why we hunger to provide breakthrough therapy in the basis of state-of-the-art science and innovative technology